Chronic Kidney Disease Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies

Chronic Kidney Disease Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Chronic Kidney Disease therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

As per DelveInsight, the Chronic Kidney Disease (CKD) therapeutics market is anticipated to grow immensely in the coming years owing to the increasing prevalent population of Chronic Kidney Disease (CKD) patients in the 7MM, along with the expected entry of premium price asset such Anti-inflammatories, Prolyl hydroxylase and IL-6 inhibitors, which will have a significant impact on the treatment outlook.

Chronic Kidney Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Chronic Kidney Disease Market. 

The Chronic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Chronic Kidney Disease Pipeline Analysis

Chronic Kidney Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Chronic Kidney Disease and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Chronic Kidney Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Route of Administration

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal


Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide

  • Peptide

  • Small molecule


Learn How the Ongoing Clinical & Commercial Activities will Affect the Chronic Kidney Disease Therapeutic Segment @


Chronic Kidney Disease Therapeutics Landscape

There are approx. 50+ key companies developing therapies for Chronic Kidney Disease. Currently, KBP Biosciences is leading the therapeutics market with its Chronic Kidney Disease drug candidates in the most advanced stage of clinical development. 

The Leading Companies in the Chronic Kidney Disease Therapeutics Market Include:

KBP Biosciences, Eli Lilly and Company, Novo Nordisk, Prokidney, Boryung Pharmaceutical, Boehringer Ingelheim, Cadila Healthcare Limited, AM-Pharma, DiaMedica Therapeutics, Allena Pharmaceuticals, AstraZeneca, Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Scohia Pharma, Unicycive Therapeutics, Senda Biosciences, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, Oisin Biotechnologies, Aria Pharmaceuticals, RedHill Biopharma, BERGENBIO, GNI Group, and many others.

Chronic Kidney Disease Drugs Covered in the Report Include:

  • ALLN-346: Allena Pharmaceuticals

  • Cellgram-CKD: Pharmicell

  • Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company

  • ION532: Ionis Pharmaceuticals

  • KBP-5074: KBP Biosciences

  • MEDI8367: AstraZeneca

  • Runcaciguat: Bayer

  • TXR-1208: Aria Pharmaceuticals

  • UNI-494: Unicycive Therapeutics

  • US-APR2020: Kibow Pharma

  • Zibotentan+Dapagliflozin: AstraZeneca

  • Ziltivekimab: Novo Nordisk

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Chronic Kidney Disease Current Treatment Patterns

4. Chronic Kidney Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Chronic Kidney Disease Late Stage Products (Phase-III)

7. Chronic Kidney Disease Mid-Stage Products (Phase-II)

8. Chronic Kidney Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chronic Kidney Disease Discontinued Products

13. Chronic Kidney Disease Product Profiles

14. Key Companies in the Chronic Kidney Disease Market

15. Key Products in the Chronic Kidney Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Chronic Kidney Disease Unmet Needs

18. Chronic Kidney Disease Future Perspectives

19. Chronic Kidney Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Other Trending Healthcare Reports By DelveInsight

Chronic Kidney Disease Market Outlook

Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology, as well as the Lupus Nephritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States